Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
HER2
Biotech
Eisai's abandoned Enhertu challenger set to live on at BlissBio
Eisai once identified BB-1701 as a potential best-in-class molecule, citing its eribulin-based payload-linker technology as a differentiator.
Nick Paul Taylor
Mar 21, 2025 7:20am
Roche companion test moves into HER2-ultralow breast cancer
Feb 4, 2025 12:00pm
OS' drug stopped lung cancer from returning in 3rd of patients
Jan 15, 2025 9:55am
Carisma axes sole clinical candidate, lays off 34% of staff
Dec 9, 2024 10:58am
ESMO: Jazz HER2 bispecific posts 59% survival at 30 months
Sep 16, 2024 3:00am
Boehringer, Bayer advance lung cancer meds toward Enhertu battle
Sep 9, 2024 4:43pm
